Prognostic Impact of Extramedullary Infiltration in Pediatric Low-risk Acute Myeloid Leukemia: A Retrospective Single-center Study Over 10 Years.

Clinical Lymphoma, Myeloma & Leukemia
Guan-Hua HuLe-Ping Zhang

Abstract

The impact of extramedullary infiltration (EMI) on the clinical outcomes of pediatric patients with acute myeloid leukemia (AML) are controversial. A total of 214 pediatric patients with low-risk AML were classified as having EMI (central nervous leukemia [CNSL] and/or myeloid sarcoma [MS]) and not having EMI. Patients with isolated MS before AML diagnosis by bone marrow examination were confirmed with histopathologic examination. For patients diagnosed with AML by bone marrow examination, a thorough physical examination and radiologic imaging were used to confirm MS. Male gender, a high white blood cell count, the FAB-M5 subtype, t(8;21) and t(1;11) abnormalities, and c-KIT mutations were associated with EMI. The presence of MS was associated with a low complete remission rate (63.6% vs. 79.4%; P = .000) and poor 3-year relapse-free survival (RFS) (62.6% ± 7.5% vs. 87.0% ± 2.8%; P = .000) and 3-year overall survival (73.5% ± 7% vs. 88.8% ± 2.6%; P = .011). Multivariate analysis revealed that MS was a poor prognostic factor for RFS and overall survival. Bone infiltration was an independent risk factor for inferior RFS with MS. Patients with CNSL had a low complete remission rate (58.3% vs. 77.2%; P = .045); however, CNSL did no...Continue Reading

References

Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C ByrdC D Bloomfield
Oct 7, 2003·Journal of Pediatric Hematology/oncology·Kathryn E DusenberyWilliam G Woods
Mar 22, 2006·Pediatric Blood & Cancer·Ryoji KobayashiUNKNOWN Japanese childhood AML cooperative study group
Mar 17, 2010·Cancer Treatment Reviews·Peter Kaatsch
May 5, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christine von NeuhoffUrsula Creutzig
May 5, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christine J HarrisonBrenda E S Gibson
Sep 24, 2013·Leukemia·A FasanS Schnittger
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C Michel ZwaanGertjan J L Kaspers
Feb 7, 2016·Jornal de pediatria·Mariana Cardoso de LimaMaurício Laerte Silva
Oct 28, 2016·Paediatric Drugs·Jeffrey E Rubnitz
Apr 24, 2018·Clinical Lymphoma, Myeloma & Leukemia·Raja PramanikSameer Bakhshi
Dec 10, 2019·Current Opinion in Pediatrics·Caitlin W Elgarten, Richard Aplenc
Jan 11, 2020·Journal of Cancer Research and Clinical Oncology·Lu-Hong XuJian-Pei Fang

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Pediatric Blood & Cancer
Ryoji KobayashiJapanese childhood AML cooperative study group
Mediterranean Journal of Hematology and Infectious Diseases
Luana FianchiLivio Pagano
The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Sung Won LimChan Kum Park
© 2021 Meta ULC. All rights reserved